AstraZeneca plc (LON:AZN) announced a dividend on Thursday, July 27th, Upcoming.Co.Uk reports. Investors of record on Thursday, August 10th will be given a dividend of GBX 68.90 ($0.89) per share by the biopharmaceutical company on Monday, September 11th. This represents a dividend yield of 1.35%. The ex-dividend date is Thursday, August 10th. The official announcement can be seen at this link.
Shares of AstraZeneca plc (LON AZN) traded down 0.76% on Friday, reaching GBX 4447.00. The company’s stock had a trading volume of 1,614,494 shares. The stock has a 50-day moving average price of GBX 4,818.59 and a 200-day moving average price of GBX 4,863.31. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00. The company’s market capitalization is GBX 56.30 billion.
In other news, insider Nazneen Rahman purchased 39 shares of the stock in a transaction on Thursday, July 27th. The stock was purchased at an average price of GBX 4,370 ($56.73) per share, with a total value of £1,704.30 ($2,212.51).
ILLEGAL ACTIVITY WARNING: This news story was published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.baseball-news-blog.com/2017/08/19/astrazeneca-plc-to-issue-dividend-of-gbx-68-90-lonazn-updated.html.
AZN has been the subject of several recent analyst reports. Morgan Stanley reissued an “overweight” rating and issued a GBX 5,600 ($72.70) price target on shares of AstraZeneca plc in a report on Friday, June 23rd. Deutsche Bank AG reaffirmed a “buy” rating on shares of AstraZeneca plc in a report on Monday, May 22nd. Shore Capital reaffirmed a “sell” rating on shares of AstraZeneca plc in a report on Thursday, May 4th. Barclays PLC reaffirmed an “overweight” rating and set a GBX 6,000 ($77.89) price objective on shares of AstraZeneca plc in a report on Monday, June 5th. Finally, Liberum Capital reaffirmed a “buy” rating and set a GBX 5,500 ($71.40) price objective on shares of AstraZeneca plc in a report on Wednesday, June 14th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of GBX 4,932.67 ($64.04).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.